Medicamen Organics Limited IPO

About Medicamen Organics Limited

Medicamen Organics Limited is involved in developing, manufacturing, and distributing a broad range of pharmaceutical dosages. These include generic forms such as tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders. The company serves both state and central government institutions as well as private entities, acting as a contract or third-party manufacturer. Products are marketed to private pharmaceutical companies domestically and internationally through third-party distributors or on a loan license basis. Recently, the company has focused on establishing a direct international presence, exemplified by direct exports to Burundi in fiscal 2023 and 2024.

Operating under a B2B model, Medicamen Organics partners with various pharmaceutical companies for contract manufacturing. The company's products are distributed across India and regions including Africa, the CIS, and Southeast Asia, covering countries like Congo, Benin, Togo, Senegal, the Philippines, Myanmar, and Kenya. The company boasts two WHO GMP-approved manufacturing facilities in Haridwar, Uttarakhand, spanning 21,536 square feet, with comprehensive quality control departments and in-house testing laboratories. Certified to ISO 9001:2015, the company emphasises product development and research, contributing to a diverse product portfolio of 84 drugs, including antibiotics, anti-diabetics, and multivitamins.

Consistent quality and compliance with safety standards are central to Medicamen Organics' operations. The company continuously seeks to expand its product line with complementary offerings. A professional management team led by promoters and directors with nearly three decades of industry experience oversees operations. 

Medicamen Organics follows a contract manufacturing business model, partnering with pharmaceutical companies that market and sell the products. By March 31, 2024, the company had 84 product registrations and partnerships with 44 domestic and 12 international entities. Additionally, the company participates in government tenders, supplying products to various government institutions and leveraging advantages such as bulk orders and committed volumes. Key product categories include capsules, ointments, suspensions, dry powder sachets, and tablets.

Industry Outlook:

1. The growth of the Indian pharmaceutical market to USD 130 billion by 2030 presents substantial opportunities for Medicamen Organics Limited to expand its product offerings and market reach.
2. India supplies 20% of global generic drugs and 60% of vaccines, underscoring its critical role in global healthcare. As India maintains its status as a major supplier of generics and vaccines, Medicamen Organics Limited can leverage this position to enhance its export footprint and enter new international markets.
3. The sector has attracted significant foreign direct investment (FDI), with FDI inflows reaching USD 21.46 billion by March 2023. The FDI inflow and supportive government policies can facilitate Medicamen Organics Limited's securing funding for expansion, innovation, and capacity building, driving future growth and competitiveness.

Medicamen Organics Limited IPO Objectives 

The company plans to allocate the net proceeds from the issuance to the following purposes:

1. Allocate up to ₹300 lakhs for registering products in international markets.
2. Spend up to ₹225 lakhs to update the plant and increase production capacity.
3. Utilise up to ₹400 lakhs to meet working capital requirements.
4. Utilise remaining funds for general corporate purposes.

Peer Details

The following are the listed industry peers of Medicamen Organics Limited:

1. Brooks Laboratories Limited
2. Cian Healthcare Limited
3. Zenotech Laboratories Limited

How to Check the Allotment Status of the Medicamen Organics Limited IPO?

Steps to check IPO allotment status on Angel One’s app:

• Log in to the Angel One app
• Go to the individual order details page of the IPO that you had applied for. 
• Check the IPO allotment status. As such, Angel One will notify you of your IPO allotment status via push notification, email, and SMS.

Contact Details of Medicamen Organics Limited

Registered office: 10 Community Centre No 2 Ashok Vihar Phase II, New

Delhi, Delhi, 110052, India.

Email:  cs@mediorganics.in

Phone: +91-9818222845